阿托伐他汀钙联合依折麦布对冠心病的治疗效果与安全性研究  

Efficacy and Safety of Atorvastatin Calcium Combined with Ezetimibe in the Treatment of Coronary Heart Disease

作　　者：尚秀芝 SHANG Xiuzhi(Department of Pharmacy,the First Rehabilitation Hospital of Shandong Province,Linyi,Shandong 276032,China)

机构地区：[1]山东省第一康复医院药剂科,山东临沂276032

出　　处：《中国医药指南》2025年第2期68-70,共3页Guide of China Medicine

摘　　要：目的探讨临床对冠心病患者选择阿托伐他汀钙+依折麦布药物联合治疗后获得的临床效果,并观察对不良反应产生的影响。方法选取山东省第一康复医院2020年3月至2023年7月80例冠心病患者的临床治疗情况展开回顾性分析,依据不同用药方法完成治疗分组。单纯应用阿托伐他汀钙药物治疗的为对照组,共40例;在阿托伐他汀钙药物的基础上,添加依折麦布药物治疗的为研究组,共40例。对比两组的疗效、心功能指标、血脂指标以及不良反应。结果研究组冠心病患者治疗总有效率(97.50%)高于对照组(80.00%)(P<0.05)。治疗后,研究组冠心病患者除NT-ProBNP低于对照组之外,CO水平、SV水平、LVEF水平测定结果均高于对照组(均P<0.05)。治疗后,研究组冠心病患者除高密度脂蛋白胆固醇水平高于对照组之外,甘油三酯水平、总胆固醇水平、低密度脂蛋白胆固醇水平测定结果均低于对照组(均P<0.05)。研究组不良反应总发生率低于对照组(P<0.05)。结论临床对冠心病患者在治疗期间,阿托伐他汀钙+依折麦布药物的联合应用,可将疗效提升,将患者的血脂水平以及心功能双重改善,有效减少不良反应。Objective To explore the clinical efficacy and safety of atorvastatin calcium+ezetimibe treatment in patients with coronary heart disease.Methods A total of 80 coronary heart disease patients treated at Shandong Province First Rehabilitation Hospital from March 2020 to July 2023 were retrospectively analyzed.The patients were divided into two groups based on different medication methods:the control group,consisting of 40 cases treated solely with atorvastatin calcium medication,and the study group,which included 40 cases treated with atorvastatin calcium plus ezetimibe.The efficacy,cardiac function indicators,lipid profiles,and adverse reactions of the two groups were compared.Results The total effective rate of treatment in the study group for coronary heart disease patients(97.50%)was higher than that in the control group(80.00%)(P<0.05).After treatment,except for NT-ProBNP being lower than in the control group,the levels of CO,SV,and LVEF in the study group were all higher than those in the control group(all P<0.05).After treatment,except for the level of high-density lipoprotein cholesterol being higher than in the control group,the levels of triglycerides,total cholesterol,and low-density lipoprotein cholesterol in the study group were all lower than those in the control group(all P<0.05).The overall incidence of adverse reactions in the study group was lower than that in the control group(P<0.05).Conclusions In clinical treatment of patients with coronary heart disease,the combined application of atorvastatin calcium plus ezetimibe can significantly improve the efficacy,double improve the blood lipid level and cardiac function of patients,and effectively reduce adverse reactions.

关 键 词：冠心病 阿托伐他汀钙 依折麦布 治疗效果 心功能 血脂 安全性 

分 类 号：R541.4[医药卫生—心血管疾病]